Herpes Virus Expert, Dr. Stephen Sacks Joins Jenex Advisory Committee
FOR IMMEDIATE RELEASE
June 10, 2002
Burlington, Ontario
THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN), is pleased to announce the addition of Dr. Stephen Sacks to its Corporate Advisory Committee. Dr. Sacks is a renowned clinician in infectious diseases with an internationally recognized expertise in herpes virus infections. In the clinical research area, he is best known for establishing several of the clinical trial models now widely used for the study of new herpes treatments. As a basic scientist, Dr. Sacks has been interested in antiviral resistance and mechanism of action of new treatments and has authored the best-selling book on the management of herpes called The Truth About Herpes, now in its IVth edition.
Dr. Sacks will advise the Corporation on future clinical requirements as it relates to herpes virus research and other potential indications for their Thermal Therapy Technology. In his Corporate Advisory capacity, Dr. Sacks will make an important contribution to current and future regulatory (i.e. TPP, FDA etc.) submissions.
Dr. Stephen Sacks
Dr. Sacks is currently a Professor at the Department of Pharmacology and Therapeutics, Faculty of Medicine at The University of British Columbia and President and CEO of Viridae Clinical Sciences Inc. His primary areas of expertise are herpes infections and hepatitis B and C infections, clinical trial development and management. Dr. Sacks received his medical training at the University of Cincinnati (1975). His postgraduate training specialized in internal medicine at the University of Toronto and infectious diseases at Stanford University Medical Center.
Dr. Sacks has also served on the Herpes Advisory Boards of several multinational pharmaceutical firms including Novartis, GlaxoSmithKline, 3M and Eli Lilly. He serves on the editorial boards of several academic journals including Herpes, Antiviral Therapy, Biotherapy, Journal of Antimicrobial Chemotherapy, Skin Therapy Letter and Expert Opinion on Pharmacotherapy.
About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation has developed and patented a thermal therapeutic device for the prevention of cold sores. Patents in fifteen countries, including the United States, Canada, Australia, and the E.E.C protect the technology. Clearance from regulatory, Therapeutic Products Programme (TPP), in Canada has been received to market their thermal therapy device over-the-counter (OTC) with the claim “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”. A medical device license has been issued by TPP in accordance with Medical Device Regulations. Jenex is the first company to receive clearance to market from a significant regulatory body to make the Prevention claim for cold sores.
The Corporation is currently seeking approval from the FDA to make a similar marketing claim in the United States.
Jenex is pursuing a strategic corporate partner to license and commercialize their thermal therapy technology. Several multinational Companies have signed Confidentiality Agreements and are in various stages of due diligence.
The HSV-1 virus that causes cold sores, is endemic in North America, and is estimated to affect 80% of the population. As the only product clinically proven to prevent the outbreak of cold sores, the Corporation’s thermal therapy product has the potential to dominate a large and underdeveloped market.
“Prevention is the Solution”
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release.
The Jenex Corporation
207-940 Sheldon Court
Burlington, Ontario, L7L 5K6
Michael A. Jenkins, President
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: jenex@sprint.ca
Website: www.jenexcorp.com
